And it has been widely confirmed that in patients with diabetes, after receiving GLP-1 receptor agonist treatment, the level of IL-6 decreases and pancreatic islet function improves (41, 42), suggesting that GLP-1 may affect the function of pancreatic islets through the negative feedback of IL-6. This evidence concerns the gene GCG and diabetes mellitus.